These are almost entirely, to date, raised against the extracellular domains of cell-surface proteins that are identified as viable tumor targets, though there are recent developments in generating scFvs that recognize intracellular tumor antigens with limited MHC restriction (which is a limiting factor in TCR-T cell therapy) through display technologies [37, 38] or using structural analysis to drive rationale engineering to optimize the binder [39, 40]. Here, HLA-C is linked to neoplasm.